Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lapatinib + pemetrexed in second-line advanced or metastatic non-small cell lung cancer
2007-002472-34Phase 2Terminated
- Sponsor
- GSK
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoints: Optimal treatment regimen determination and Antitumor activity of lapatinib. Started Jun 2007; status: terminated.
02
Drugs
lapatinibpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-002472-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002472-34.